News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

HEALTHPOINT Focused On Supply Availability, Service To Customers As IODOSORB(R) Gel, IODOFLEX(R) Pad Licensing Agreement Expires



12/23/2005 10:58:07 AM

FORT WORTH, Texas, Dec. 22 /PRNewswire/ -- Michael E. Steadman, President of Tissue Management for HEALTHPOINT(R), Ltd., a DFB Pharmaceuticals Inc. affiliate company, has announced that HEALTHPOINT will strive for an uninterrupted supply of IODOSORB(R) Gel and IODOFLEX(R) Pad absorbent antimicrobials to their customers as the licensing agreement with Smith & Nephew for these products expires. This change will be effective March 31, 2006. After that date, Smith & Nephew will assume responsibility for the brands.

"In order for customers to continue to receive the products they need to help their patients, we are working diligently with Smith & Nephew to ensure supply is uninterrupted," said Mr. Steadman. "Our goal is to support our customers so they can provide top quality care for patients. Count on continued responsiveness and communication from HEALTHPOINT."

Until March 31, HEALTHPOINT will continue to supply Iodosorb and Iodoflex to wholesalers and distributors, a supply chain that begins with Smith & Nephew, according to Mr. Steadman. Wholesalers and distributors will supply customers until inventories are depleted.

"We will honor all contract prices for as long as these products remain available through HEALTHPOINT," emphasized Sarah Young, HEALTHPOINT's product manager for Iodosorb and Iodoflex.

Ms. Young encouraged customers to continue to order IODOFLEX 5 gram: 8213- 0090-05, IODOFLEX 10 gram: 8213-0090-10, and IODOSORB 40 gram: 8213-0100-40 until local distributors provide notification that supplies have been depleted.

Mr. Steadman reaffirmed his company's dedication to meeting market needs.

"We want to state our commitment to our customers and to the ongoing development of innovative prescription pharmaceuticals, biologics and technologies that improve treatment and outcomes for healthcare professionals and their patients," said Mr. Steadman. "We thank our customers for their continued support of HEALTHPOINT."

Since its inception in 1992, HEALTHPOINT has established a U.S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical indications. An aggressive research and development effort has brought HEALTHPOINT's unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. HEALTHPOINT, with over 300 employees, is a DFB Pharmaceuticals, Inc. affiliate company. HEALTHPOINT is based in Fort Worth, Texas. Visit HEALTHPOINT's web site at http://www.healthpoint.com .

HEALTHPOINT, Ltd.

CONTACT: Sarah Young of HEALTHPOINT, Ltd., +1-800-441-8227, orSarah.Young@healthpoint.com


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES